Product
CoronaVac
Aliases
CoronaVac COVID-19 vaccine, CoronaVac Vaccine
16 clinical trials
11 indications
Indication
COVID-19Indication
Adverse Reaction to ImmunizationIndication
Chronic Liver DiseaseIndication
Lung FunctionIndication
Exercise CapacityIndication
Quality of LifeIndication
Rheumatic DiseasesIndication
HIV InfectionsIndication
HIV/AIDSIndication
Safety IssuesIndication
ImmunogenicityClinical trial
Serological Response to mRNA and Inactivated COVID-19 Vaccine in Health Care Workers in Hong KongStatus: Completed, Estimated PCD: 2021-12-31
Clinical trial
A Randomized, Double-blind, Positive-controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of SCTV01E (A COVID-19 Alpha/Beta/Delta/Omicron Variants S-Trimer Vaccine) in Healthy PeopleStatus: Not yet recruiting, Estimated PCD: 2023-08-25
Clinical trial
A Single Center, Randomized, Open-labeled, Blind Endpoint Evaluation, Exploratory Clinical Study to Evaluate the Safety and Immunogenicity of Bivalent Vaccine V-01D-351 as a Booster Dose in Participants Aged 18 Years and Older Vaccinated 2-dose or 3-dose Inactivated COVID-19 VaccineStatus: Active (not recruiting), Estimated PCD: 2022-09-13
Clinical trial
A Multi-center, Observer-blind, Randomized, Controlled Phase 3 Study to Evaluate the Immunogenicity and Safety of Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine (SCB-2019), Administered as a Booster Dose to Adults, Who Previously Received Primary Series of a COVID-19 VaccineStatus: Completed, Estimated PCD: 2023-06-06
Clinical trial
A Clinical Trial to Assess the Immunogenicity and Safety Following a Heterologous Booster Dose of Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001 in Adults 18-59 Years of Age Completed Two- or Three-dose Inactivated COVID-19 VaccineStatus: Active (not recruiting), Estimated PCD: 2022-10-10
Clinical trial
To Compare the Reactogenicity and Immunogenicity of Recommended COVID-19 Vaccines in Young Adolescents and Children in Hong KongStatus: Active (not recruiting), Estimated PCD: 2025-03-31
Clinical trial
A Prospective Study Comparing the Antibody Response of Subjects With Chronic Liver Disease to mRNA, Inactivated Virus and Adenovirus Vector COVID-19 VaccinesStatus: Completed, Estimated PCD: 2023-09-30
Clinical trial
Open Label, Multi-Center Phase 3 Clinical Trial to Determine Safety, Efficacy, and Immunogenicity of Booster Vaccination Against SARS-CoV-2Status: Completed, Estimated PCD: 2023-05-10
Clinical trial
Multicenter,Randomized,Observational Blind Phase IIB Clinical Trial to Evaluate the Effectiveness,Immunogenicity and Safety of Two Doses of CoronaVac (Sinovac) Vaccine Against Two Doses of Inactivated COVID-19 Vaccine (TURKOVAC) in Healthy Adolescent (12-18 Years) SubjectsStatus: Completed, Estimated PCD: 2023-05-15
Clinical trial
Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial For Evaluation of Efficacy and Safety of SARS-CoV-2 Vaccine (Vero Cell), InactivatedStatus: Completed, Estimated PCD: 2022-06-30
Clinical trial
Efficacy, Immunogenicity, and Safety of the Two-Dose Inactivated COVID-19 Vaccine (TURKOVAC) Versus the Two-Dose CoronaVac (Sinovac) Vaccine in Healthy Subjects: A Randomized, Observer-Blinded, Phase III Clinical TrialStatus: Completed, Estimated PCD: 2023-03-08
Clinical trial
Effectiveness of Pfizer-BioNTech BNT162b2 mRNA COVID-19 Vaccine on Symptomatic SARS-CoV-2 Infection and COVID-19-related Hospitalizations, Mortality, and Long-term Consequences in Brazil: a Real-world Evidence StudyStatus: Completed, Estimated PCD: 2022-06-20
Clinical trial
A Real-world Evidence Study of BNT162b2 mRNA Covid-19 Vaccine Among Children Aged 5 to 11 Years in BrazilStatus: Completed, Estimated PCD: 2023-04-30
Clinical trial
Lung Function, Exercise Capacity, and Serology Responses in Patients With COVID-19Status: Recruiting, Estimated PCD: 2024-08-18
Clinical trial
Double-Blind, Randomized, Controlled, Multi-Centered, Phase 2 Clinical Trial to Determine the Safety, Efficacy, and Immunogenicity of Booster Vaccination Against SARS-CoV-2Status: Completed, Estimated PCD: 2022-03-09
Clinical trial
Immunogenicity and Safety of the CoronaVac Vacccine in Patients With Autoimmune Rheumatic Diseases and People Living With HIV/AIDSStatus: Completed, Estimated PCD: 2023-11-27